Dopamine Depleting Drugs
|
|
- Scott Chapman
- 6 years ago
- Views:
Transcription
1 Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas phone Dopamine Depleting Drugs Introduction Movement disorders are neurological conditions manifested either by slowness of movement, seen in Parkinson's disease, or abnormal involuntary movements, the so-called hyperkinesias (hyper: too much, kinesis: movement). The hyperkinesias are characterized by excessive, involuntary, repetitive, twisting or random jerk-like movements which may involve the face, limbs, or the entire body. One form of hyperkinesia is tardive dyskinesia, manifested typically by repetitive, chewing mouth and jaw movements. Repetitive (stereotypic) movements associated with tardive dyskinesia may also involve the trunk (rocking movements) and limbs. Tardive dyskinesia is caused by exposure to certain antipsychotics (medications used to treat hallucinations and disorders of thinking) or antiemetics (medications against nausea and vomiting). Although often transient, tardive dyskinesia may be permanent. Other examples of hyperkinesias include chorea (which means "dance" in Greek, and are brief, irregular, continuous jerky-like movements that randomly involve different muscles, as seen in conditions such as Huntington's disease), athetosis (subtle twisting and writhing movements often accompanying chorea, seen for example in cerebral palsy), ballism (large amplitude, flinging movements usually of one arm or leg, most commonly following a lesion, such as a stroke, in a specific region in the brain called the subthalamic nucleus), motor and phonic tics (typically associated with Tourette syndrome), dystonia (intermittent or sustained muscle contractions producing abnormal, often repeated, postures and/or movements), myoclonus (brief muscle jerks), stereotypies (constant repetition of certain gestures and seemingly purposeful coordinated movements such as seen in chewing movements of orofacial tardive dyskinesia or body-rocking movements in 1
2 children with autism), and akathisia (subjective feeling of "inner" restlessness and inability to stay still). The neurochemical alterations underlying involuntary movement disorders are not well understood, but excess dopamine or increased sensitivity of dopamine receptors have been postulated to play a dominant role in many hyperkinetic movement disorders, particularly tardive dyskinesia, Huntington's disease and Tourette syndrome. The traditional antipsychotic or antiemetic drugs, also called neuroleptics, block dopamine receptors and are sometimes used to treat the various hyperkinetic movement disorders. However, these drugs carry the risk of tardive dyskinesia and, therefore, are not appropriate for the chronic therapy of movement disorders. Other drugs that act by reducing the dopaminergic transmission and thus ameliorate hyperkinesias include reserpine, tetrabenazine (TBZ; Xenazine), deutetrabenazine (DBZ; Austedo) and valbenzine (VBZ; Ingrezza). These drugs cause depletion of dopamine in the brain, but reserpine also causes dopamine depletion in the peripheral nervous system and therefore may cause low blood pressure, diarrhea and other adverse effects. The primary pharmacologic action of TBZ, DBZ and VBZ is depletion of dopamine in the central nervous system by inhibiting the human vesicular monoamine transporter isoform 2 (hvmat2). Tetrabenazine (TBZ) In 1979, the Food and Drug Administration granted Dr. Jankovic Investigational Exemption for a New Drug, a special permission to use TBZ in various movement disorders. Since that time Dr. Jankovic and his colleagues at the Parkinson s Disease Center and Movement Disorders Clinic at Baylor College of Medicine have accumulated long-term experience with this drug in well over a thousand patients with a large variety of hyperkinesias. Data from double-blind, placebo-controlled trials conducted at Baylor and also as part of a large multicenter study (TETRA-HD) as well as longitudinal data based on observational experience at Baylor over the 2
3 past quarter century was submitted to the FDA. In December 2007, an independent advisory committee concluded that TBZ is effective and safe and unanimously recommended to the FDA an approval of TBZ (Xenazine) for the treatment of chorea associated with Huntington's disease, which was finally granted on Aug. 15, This approval was provided under the FDA's orphan products program, which is aimed at developing treatments for conditions affecting fewer than 200,000 people (Huntington's disease affects 30,000 people in the United States). Although not approved by the FDA yet, TBZ is also used to treat patients with Tourette's syndrome and tardive dyskinesia. Although considered safe when appropriately administered and monitored, TBZ does have potential side effects, such as drowsiness, changes on electrocardiogram (prolonged QT interval), slowness of movement (parkinsonism), mood changes (depression), nervousness/anxiety and restlessness (akathisia). The labeling for TBZ draws special attention to potential depression and suicidality and recommended genotyping patients (for CYP2D6) to determine if they are slow metabolizers when dosage above 50 mg per day is prescribed (see package insert for additional precautions, contraindications and other prescribing information). The side effects of TBZ are reversible, meaning that they resolve with either dose reduction or drug cessation. Most importantly, there has been no documented cases of TBZ-induced tardive dyskinesia, and, therefore, this dopamine depleting agent has a distinct advantage over the dopamine-blocking agents (neuroleptics) in the treatment of a variety of hyperkinetic movement disorders. Combination of tetrabenazine with some other medications might cause potentially dangerous side effects so make sure your neurologist and other prescribing physicians are aware of all medications you are taking including overthe-counter drugs. If you have any additional questions about Xenazine, please call the Xenazine Information Center at (888)
4 Deutetrabenazine (DBZ) DBZ is chemically similar to TBZ, except for the incorporation of deuterium ( heavy hydrogen, a type of hydrogen with higher mass allowing for stronger chemical bonds), which makes the drug more resistant to metabolism by the human body. This creates several advantages compared to TBZ: steadier drug levels in the blood, lower peak concentration, lower doses and less frequent (twice daily vs three times daily) drug administration while maintaining the same relative effect. For these reasons, DBZ is felt to be better tolerated compared to TBZ. The mechanism of action and side effects of DBZ are the same as TBZ. DBZ has been studied in several large trials, including several with participation of patients and clinicians at Baylor, involving patients with Huntington s disease (FIRST-HD), Tourette syndrome and tardive dyskinesia (ARM-TD and AIM-TD). In the FIRST-HD trial, while reporting significant symptomatic benefit, less than a third as many patients as in TETRA-HD (TBZ) reported side-effects of sleepiness, difficulty falling asleep, fatigue and depression. Although this reaffirms the clinical experience that DTBZ may be better tolerated than TBZ, a direct comparison between the two studies/drugs should be avoided due to several differences in the study populations and how the studies were executed. Due to the body of evidence presented in FIRST-HD, DBZ received FDA approval in 2017 as a treatment for chorea in Huntington s disease. Based on the positive results of ARM-TD and AIM- TD, DBZ further received FDA approval for the treatment of tardive dyskinesia in The drug currently being marketed for these indications by Teva Pharmaceutical Industries Ltd. under the trade name Austedo. Similar to TBZ, DBZ is also used off-label for Tourette s syndrome and tardive dyskinesia. The sideeffects of DBZ are similar to those of TBZ and similarly resolve upon dose reduction or drug withdrawal. DBZ has not been associated with tardive dyskinesia. DBZ is typically dosed as 6-24mg twice daily. If you have any additional questions about Austedo, please call Teva s Shared Solutions at (800) Valbenazine (VBZ) 4
5 VBZ is a prurified prodrug of TBZ, meaning that it is metabolized (converted) into some of the same active substances as TBZ. Due to its pharmacological profile, VBZ is administered once daily compared to three times daily for TBZ, and is felt to be better tolerated than TBZ. The mechanism of action and side effect profile of VBZ are the same as TBZ and DBZ. VBZ has been studied for the treatment of Tourette s syndrome (T-Forward and T- Force GREEN) and tardive dyskinesia (KINECT-3 and -4). Since VBZ had been designated as a breakthrough therapy by the FDA in 2014, this helped pave the way for priority review of the drug when the results of KINECT-3, a multicenter, randomized trial, became available. This led to the FDA s first ever approval of a drug for the treatment of tardive dyskinesia on April 11 th, It is currently being marketed for this indication by Neurocrine Biosciences Inc. under the trade name Ingrezza. VBZ is also used off-label for chorea in Huntington s disease and Tourette s syndrome. The side-effects of VBZ are similar to those of TBZ and DBZ and similarly resolve upon dose reduction or drug withdrawal. VBZ has not been associated with tardive dyskinesia. VBZ is typically dosed as 80mg once daily. If you have any additional questions about Ingrezza, please call the INBRACE Support Program at (844) Selected References Adam OR, Jankovic J. Symptomatic Treatment of Huntington Disease. Neurotherapeutics 2008; 5: Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009; 9: 62. Frank S, Jankovic J. Advances in the pharmacological management of Huntington s disease. Drugs 2010; 70: Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin. Neuropharmacol. 2008; 31:
6 Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA 2016; 316: 40. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am. J. Psychiatry 2017; 174: Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2006; 66: Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a doubleblind crossover study. Ann. Neurol. 1982; 11: Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv. Neurol. 1983; 37: Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol. 1995; 18: Jankovic J. Treatment of hyperkinetic movement disorders. Lancet. Neurol. 2009; 8: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother. 2016; 17: Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev. Neurother. 2011; 11: Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette s syndrome. Neurology 1984; 34: Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al. Deutetrabenazine in Tics Associated with Tourette Syndrome. Tremor Other Hyperkinet. Mov. (N. Y). 2016; 6: 422. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington s disease. Mov. Disord. 2007; 22: Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord. 2007; 22:
7 Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin. Neuropharmacol. 2006; 29: Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 2006; 6: Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann. Pharmacother. 2011; 45: Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry 1999; 156: Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J. Child Neurol. 2008; 23: Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine Treatment for Huntington s Disease-Associated Chorea. Clin. Neuropharmacol. 2002; 25: Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: Treatment of tardive dyskinesia. Drugs 2016; 76: Additional Information For further information about the manufacturing and distribution of these medications, visit Xenazine ( Austedo ( and Ingrezza ( Joseph Jankovic, M.D. 7
Xenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: November 30, 2018 Xenazine Description Xenazine (tetrabenazine)
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.12 Subject: Xenazine Page: 1 of 5 Last Review Date: December 8, 2017 Xenazine Description Xenazine
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: June 12, 2014 Xenazine Description Xenazine (tetrabenazine)
More informationAustedo. Austedo (deutetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.15 Subject: Austedo Page: 1 of 6 Last Review Date: September 15, 2017 Austedo Description Austedo
More informationVesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza )
Vesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza ) Applies to all products administered or underwritten by Blue Cross and
More informationHuntington s disease
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Huntington s disease Diagnosis Huntington s
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Austedo TM GENERIC NAME Deutetrabenazine MANUFACTURER Teva Pharmaceuticals USA, Inc. DATE OF APPROVAL August 30, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prime Therapeutics will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6514ks-ingr.pdf
More informationDoctor Discussion Guide
Doctor Discussion Guide Are you experiencing movements in the face, tongue, or other body parts that cannot be controlled? Discussing these movements with your doctor is the first step toward managing
More informationIngrezza. Ingrezza (valbenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.29 Subject: Ingrezza Page: 1 of 5 Last Review Date: December 8, 2017 Ingrezza Description Ingrezza
More informationFor Tardive Dyskinesia
A LOOK AT VMAT2 INHIBITORS DECEMBER 2017 For Tardive Dyskinesia Tardive dyskinesia (TD) is a repetitive, involuntary movement disorder caused by prolonged use of medications that block the dopamine receptor,
More informationCould your uncontrollable movements be tardive dyskinesia (TD)? There s a treatment with INGREZZA.
Lip smacking, eye blinking, dancing hands and fingers, hip jerking... Could your uncontrollable movements be tardive dyskinesia (TD)? There s a treatment with INGREZZA. Approved for adults with TD TD can
More informationAUSTEDO (deutetrabenazine) oral tablet INGREZZA (valbenazine) oral capsule XENAZINE (tetrabenazine) oral tablet Tetrabenazine oral tablet
Tetrabenazine oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationPresented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA.
Original Presentations Key Words: amines, antipsychotic agents, double-blind method, mood disorders, psychopharmacology, psychotic disorders, schizophrenia, tardive dyskinesia, valbenazine Efficacy of
More informationCompared with first-generation antipsychotics,
Deutetrabenazine for tardive dyskinesia Jonathan M. Meyer, MD Compared with first-generation antipsychotics, second-generation antipsychotics (SGAs) have a lower risk for extrapyramidal symptoms. Yet tardive
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationDoctor Discussion Guide
Doctor Discussion Guide Making an informed treatment decision begins with having a meaningful discussion with your doctor. Print this resource and bring it with you to your next doctor s appointment. Answer
More informationA Helpful Guide When Starting
A Helpful Guide When Starting Approved Uses AUSTEDO is a prescription medicine that is used to treat: the involuntary movements (chorea) of Huntington s disease. AUSTEDO does not cure the cause of the
More informationThe Importance of Taking AUSTEDO (deutetrabenazine) Tablets as Prescribed
The Importance of Taking AUSTEDO (deutetrabenazine) Tablets as Prescribed Approved Uses AUSTEDO is a prescription medicine that is used to treat: the involuntary movements (chorea) of Huntington s disease.
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationAustedo. (deutetrabenazine) New Product Slideshow
Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationAdvances in the Management of Tardive Dyskinesia
Advances in the Management of Tardive Dyskinesia Supported by an educational grant from Teva Pharmaceuticals. Rakesh Jain, MD, MPH Clinical Professor Department of Psychiatry Texas Tech Health Sciences
More informationUS Tardive Dyskinesia Market: Size, Trends & Forecasts ( ) December 2016
US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025) December 2016 US Tardive Dyskinesia Market Report Scope of the Report The report entitled US Tardive Dyskinesia Market: Size, Trends &
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Austedo) Reference Number: CP.PHAR.341 Effective Date: 06.13.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationFor the treatment of chorea associated with Huntington s disease (HD)
For the treatment of chorea associated with Huntington s disease (HD) Approved Uses AUSTEDO is a prescription medicine that is used to treat: the involuntary movements (chorea) of Huntington s disease.
More informationPhenomenology of Movement Disorders
Phenomenology of Movement Disorders Raja Mehanna MD Anatomical reasoning Anatomical reasoning Phenomenological reasoning Abnormal movement Hypokinetic Hyperkinetic Ataxia Video 1 But there is a tremor!
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Stakeholder Input Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Draft Background and Scope May 8, 2017 This scoping document was developed with extensive
More informationGet to know Teva s Shared Solutions
Get to know Teva s Shared Solutions Call Teva s Shared Solutions Your partner, here to at 1-800-887-8100 support you Approved Uses AUSTEDO (deutetrabenazine) tablets is a prescription medicine that is
More informationCould your uncontrollable movements be tardive dyskinesia (TD)?
Could your uncontrollable movements be tardive dyskinesia (TD)? For adults with TD, there's a convenient treatment with INGREZZA: One capsule, once daily. Important Information Approved Use INGREZZA (valbenazine)
More informationSubject: Austedo (deutetrabenazine) Original Effective Date: 3/8/2018. Policy Number: MCP-307. Revision Date(s):
Subject: Austedo (deutetrabenazine) Original Effective Date: 3/8/2018 Policy Number: MCP-307 Revision Date(s): Review Date: 3/8/2018 MCPC Approval Date: 3/8/2018 DISCLAIMER This Molina Clinical Policy
More informationPackage leaflet: Information for the user. Tardiben 25 mg tablets. Tetrabenazine
PACKAGE LEAFLET 1 Package leaflet: Information for the user Tardiben 25 mg tablets Tetrabenazine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationHow to Effectively Manage the Motor Symptoms of HD
How to Effectively Manage the Motor Symptoms of HD Yvette Bordelon, MD, PhD Associate Clinical Professor of Neurology David Geffen School of Medicine at UCLA The information provided by speakers in workshops,
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Stakeholder Input Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Revised Background and Scope June 9, 2017 This scoping document was developed with extensive
More informationMOVING TOWARD THE FUTURE: NEW DEVELOPMENTS IN THE MANAGEMENT OF TARDIVE DYSKINESIA
MVING TWARD THE FUTURE: NEW DEVELPMENTS IN THE MANAGEMENT F TARDIVE DYSKINESIA Learning bjectives Apply a systematic approach to assessing suspected drug-induced movement disorders Discuss the diagnosis
More informationNeurocrine Biosciences, Inc. THE NEUROENDROCRINE COMPANY
Neurocrine Biosciences, Inc. THE NEUROENDROCRINE COMPANY Safe Harbor Statement In addition to historical facts, these slides contain forward-looking statements that involve a number of risks and uncertainties.
More informationDisorders of Movement M A R T I N H A R L E Y N E U R O L O G Y
Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Educational Objectives Improved history taking in patients with movement disorders. Develop a systematic approach to observing and describing
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Final Evidence Report December 22, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Evidence Report November 21, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationPackage leaflet: Information for the user. Tetrabenazine 25 mg tablets. tetrabenazine
Package leaflet: Information for the user Tetrabenazine 25 mg tablets tetrabenazine Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationSubject: Xenazine (tetrabenazine) Original Effective Date: 12/3/09. Policy Number: MCP-075 Revision Date(s): 10/30/2013; 7/10/2018
Subject: Xenazine (tetrabenazine) Original Effective Date: 12/3/09 Policy Number: MCP-075 Revision Date(s): 10/30/2013; 7/10/2018 Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 MCPC Approval Date: DISCLAIMER
More informationIngrezza. (valbenazine) New Product Slideshow
Ingrezza (valbenazine) New Product Slideshow Introduction Brand name: Ingrezza Generic name: Valbenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and Formulation:
More informationDrugs used in Huntington s. disease
Drugs used in Huntington s HD can intensify in next generation disease The number of CAG repeats The age in which the symptom of HD to appear healthy person ill person dead person Drugs used in Huntington
More informationSmall-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014
Small-Cap Research December 17, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Auspex Pharmaceuticals Inc. ASPX SD-809 Hits
More informationClass Review with New Drug Evaluations: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information8/7/2017. Updates in Huntington s Disease AL Academy of Neurology Updates in HD Worldwide Prevalence of HD
Updates in Huntington s Disease AL Academy of Neurology 2017 Victor Sung, MD Director, UAB / HDSA Huntington s Disease Center of Excellence Updates in HD 2017 The UAB / HDSA Huntington s Disease Center
More informationTetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington s Disease Related Chorea
Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington s Disease Related Chorea Tatiana Yero, PharmD, BS, and Jose A. Rey, PharmD, BCPP Key words: tetrabenazine, Xenazine, Huntington
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Brand Name Medication Requests Non-Formulary Medications GMH/SA and Non- 19/21 SMI Mercy Care requires use of generic agents that are considered therapeutically equivalent by the FDA. For authorization
More informationIngrezza (valbenazine)
Ingrezza (valbenazine) Policy Number: 5.01.635 Last Review: 7/2018 Origination: 07/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ingrezza
More informationMedications for Early/Mid Stage HD
Medications for Early/Mid Stage HD Robert Y. Moore, MD, PhD, FAAN Love Family Professor Department of Neurology University of Pittsburgh Director, Huntington s s Disease Program University of Pittsburgh-UPMC
More informationTardive Dyskinesia: What Are We Missing?
Tardive Dyskinesia: What Are We Missing? Jointly provided by North American Center for Continuing Medical Education, LLC, an HMP Communications Holdings Company, and Global Medical Education. This activity
More informationJoohi Jimenez-Shahed, M.D.
(Page 1 of 7) Joohi Jimenez-Shahed, M.D. Associate Professor of Neurology Baylor College of Medicine Associate Director, Neurology Residency Program Baylor College of Medicine Director, Deep Brain Stimulation
More informationTardive Dyskinesia in the Psychiatric Setting: What We Know About the Risk
Tardive Dyskinesia in the Psychiatric Setting: What We Know About the Risk Steven C. Stoner, PharmD, BCPP Chair and Clinical Professor UMKC School of Pharmacy Division of Pharmacy Practice and Administration
More informationEMERGING TREATMENT OPTIONS FOR TARDIVE DYSKINESIA
EMERGING TREATMENT PTINS FR TARDIVE DYSKINESIA Learning bjectives Apply a systematic approach to assessing suspected adverse drug effects Discuss the diagnosis and management of TD and comorbid disorders
More informationDBSA Survey Center Less Common Medication Side Effects Survey
Summary Report: March, 2017 BACKGROUND From 10/19/16-11/21/16, DBSA administered a survey to gather information on the experiences people living with mood disorders have had with a variety of medication
More informationInvoluntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else?
Involuntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else? California Association of Nurse Practitioners Monterey, March 22, 2013 Julie Sprague-McRae, MS, RN, PPCNP-BC Ruth
More information(12) Patent Application Publication (10) Pub. No.: US 2017/ A1
(19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0151227 A1 Stamler et al. US 20170151227A1 (43) Pub. Date: (54) (71) (72) (21) (22) (63) METHODS FOR THE TREATMENT OF ABNORMAL
More informationTETRAZIN (tetrabenazine) Tablets MEDICATION GUIDE. What is the most important information I should know about TETRAZIN?
TETRAZIN (tetrabenazine) Tablets MEDICATION GUIDE Read the Medication Guide that comes with TETRAZIN before you start taking it and each time you refill the prescription. There may be new information.
More informationClass Review with New Drug Evaluations: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDifferential Diagnosis of Hypokinetic Movement Disorders
Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease
More informationMovement disorders. Dr Rick Leventer Royal Children s Hospital
Movement disorders Dr Rick Leventer Royal Children s Hospital richard.leventer@rch.org.au Movement disorders! conditions that affect the speed, fluency, quality, and ease of movement! usually affect TONE
More informationPROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION
KINECT 2 NCT01733121 Baseline Week 2 Week 4 Week 6 Valbenazine 25-75 mg Valbenazine 40 mg KINECT 3 NCT02274558 Valbenazine 80 mg a KINECT 2 and KINECT 3 were 6-week, double-blind placebo-controlled trials
More informationHyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom
Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationTardive Dyskinesia in the Psychiatric Setting: What We Know About the Risk
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2017. The content and views presented in this educational activity are those of the
More informationTardive Dyskinesia Overview
Jason P. Caplan, MD, FAPM Professor & Chair of Psychiatry Creighton University School of Medicine Phoenix, AZ Tardive Dyskinesia Overview Associated with use of dopamine receptor blockers (DRBs), including
More informationIndirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
Claassen et al. Journal of Clinical Movement Disorders (2017) 4:3 DOI 10.1186/s40734-017-0051-5 RESEARCH ARTICLE Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
More informationExtrapyramidal Symptoms Associated with Antipsychotic Use
Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and
More informationDOCTOR DISCUSSION GUIDE
DOCTOR DISCUSSION GUIDE FOR PEOPLE WITH PARKINSON S DISEASE (PD) GOCOVRI TM (amantadine) extended release capsules is the first and only FDA-approved prescription medication indicated to treat dyskinesia
More informationPsychogenic Movement Disorders
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone pdcmdc@bcm.edu www.jankovic.org Psychogenic Movement Disorders
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationIs there value in VMAT-2 inhibitors for tardive dyskinesia?
Is there value in VMAT-2 inhibitors for tardive dyskinesia? Samantha Vogel, PharmD PGY2 Psychiatric Pharmacy Resident Seton Healthcare Family The University of Texas College of Pharmacy September 22 nd,
More informationDepartment of Neurology, Rigshospitalet, 9 Blegdamsvej, PAULSON, O.B. Involuntary Movements. Tohoku J. Exp. Med., 1990, 161,
Tohoku J. Exp. Med., 1990, 161, Suppl., 21-27 Involuntary Movements OLAF B. PAULSON Department of Neurology, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark PAULSON, O.B. Involuntary Movements.
More informationAn Approach to Patients with Movement Disorders
An Approach to Patients with Movement Disorders Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon EDUCATIONAL TOOLS MDS video library
More informationParkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Dystonia Diagnosis Dystonia is a neurologic
More informationDeuterium Tetrabenazine for Tardive Dyskinesia
New Drug Review Deuterium Tetrabenazine for Tardive Dyskinesia Michael A. Cummings 1, 2, 3, George J. Proctor 1, 2, 4 5, 6, 7, Stephen M. Stahl Abstract Tardive dyskinesia remains a significant, potentially
More informationTourette s Disorder and Tics Child and Adolescent Psychopharmacology
Tourette s Disorder and Tics Child and Adolescent Psychopharmacology March 3, 2018 Barbara J. Coffey, MD, MS Division Chief, Child and Adolescent Psychiatry Professor, Department of Psychiatry and Behavioral
More informationMolina Healthcare of Texas
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Ingrezza (Marketplace) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information,
More informationCurrent Pharmacological Approaches to Reduce Chorea in Huntington s Disease
Drugs (2017) 77:29 46 DOI 10.1007/s40265-016-0670-4 REVIEW ARTICLE Current Pharmacological Approaches to Reduce Chorea in Huntington s Disease Emma M. Coppen 1 Raymund A. C. Roos 1 Published online: 17
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Tetmodis 25 mg tablets {Tetrabenazine} Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AUSTEDO safely and effectively. See full prescribing information for AUSTEDO., for oral use Initial
More informationHemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Hemifacial spasm Diagnosis Hemifacial spasm
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Draft Evidence Report October 2, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationHas a doctor, nurse or other health professional EVER told you that you had tardive dyskinesia caused by a medicine you were using?
DBSA Survey Center Experiences with Tardive Dyskinesia Summary Report: November 2017 BACKGROUND From 8/14/17-9/4/17, DBSA administered a survey to gather information on people who have been diagnosed with
More informationDYSKINESIA SYMPTOM TRACKER
DYSKINESIA SYMPTOM TRACKER FOR PEOPLE WITH PARKINSON S DISEASE (PD) GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved prescription medication indicated to treat dyskinesia
More informationDystonia. The condition can vary from very mild to severe. Dystonia may get worse over time or it may stay the same or get better.
Dystonia What are movement disorders? Movement disorders are conditions that cause involuntary body movements. With all movement disorders, abnormal signals from the brain cause patients to have trouble
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationSmall-Cap Research. Neurocrine Biosciences, Inc. (NBIX-NASDAQ) NBIX: Comparing Neurocrine s valbenazine, Auspex SD-809, and Lundbeck s Xenazine...
Small-Cap Research June 27, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Neurocrine Biosciences, Inc. NBIX: Comparing Neurocrine
More informationNeurocrine Biosciences, Inc. THE NEUROENDOCRINE COMPANY
Neurocrine Biosciences, Inc. THE NEUROENDOCRINE COMPANY Safe Harbor Statement In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties.
More informationTreating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives
Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives Interim Outcomes Report (as of November 20, 2018) Supported by an educational grant from Neurocrine Biosciences Overview Activity
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?
ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? You may have noticed a change... Levodopa is a common treatment for Parkinson s, and doctors have relied on it for decades. Over time as Parkinson s progresses,
More informationSymbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Generic name: Olanzapine and fluoxetine combination Available strengths: 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg (Zyprexa/Prozac)
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationNot an actual patient
www.takeontd.com TD CAN BE A BURDEN ON PATIENTS AND AFFECT THEIR LIVES 1 TD can be disruptive, whether they have mild, moderate, or severe TD. 2 Patients with TD may deal with many issues Abnormal and
More information